Endovascular thrombectomy and intravenous alteplase in patients with acute ischemic stroke due to large vessel occlusion: A clinical practice guideline. Issue 3 (19th September 2022)

• Record Type: Journal Article
• Authors: Ye, Zhikang; Busse, Jason W.; Hill, Michael D.; Lindsay, M. Patrice; Guyatt, Gordon H.; Prasad, Kameshwar; Agarwal, Arnav; Beattie, Cheryl; Beattie, Jim; Dodd, Cynthia; Heran, Manraj K.S.; Narayan, Sunil; Chartúir, Norita NÍ; O'Donnell, Martin; Resmini, Ilaria; Sacco, Simona; Sylaja, P N; Volders, David; Wang, Xin; Xie, Feng; Zachrison, Kori S.; Zhang, Lingli; Zhong, Hongliang; An, Zhuoling; Smith, Eric E.
• Is Part Of: Journal of evidence-based medicine. Volume 15:Issue 3(2022)
• Page Start: 263
• Page End: 271
• Publication Date: 2022-09-19
• Subjects: alteplase -- clinical practice guideline -- endovascular thrombectomy -- stroke; Evidence-based medicine -- Periodicals; Systematic reviews (Medical research) -- Periodicals; 616.005
• DOI: 10.1111/jebm.12493
• Languages: English
• ISSNs: 1756-5383

Abstract

Abstract: Aim: Whether or not use of intravenous alteplase in combination with endovascular thrombectomy (EVT) improves outcomes versus EVT alone, for acute stroke patients with large vessel occlusion presenting directly to a comprehensive stroke center, is uncertain. Methods: Six randomized trials exploring this issue were published, and we synthesized this evidence to inform a rapid guideline based on the Guidelines International Network principles and guided by the GRADE approach. Results: We enlisted an international panel that included 4 patient partners and 1 caregiver, individuals from 6 countries. The panel considered low certainty evidence that EVT alone, relative to EVT with intravenous alteplase, possibly results in a small decrease in the proportion of patients that achieve functional independence and possibly a small increase in mortality. Both effect estimates were downgraded twice due to very serious imprecision. The panel also considered moderate certainty evidence that EVT alone probably decreases symptomatic intracranial hemorrhage, versus EVT with alteplase, and combination therapy was more costly than EVT alone. As a result of the low certainty for improved recovery without impairment and mortality for combination therapy versus EVT alone, and moderate certainty for increased harm with combination therapy, the panel made a weak recommendation in favor of EVT alone for stroke patients eligible for both treatments, and initially presenting directly to a comprehensive stroke center that provides both treatments. Conclusions: Consistent with this weak recommendation, optimal patient management will likely often include co‐treatment with intravenous alteplase, depending on local circumstances and patient presentation.